Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Amgen (AMGN) said new findings from a pre-specified Phase 3 VESALIUS-CV trial analysis showed Repatha (evolocumab) reduced the risk of death by 20% in high-risk adults without a prior heart attack or ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Amgen Inc.’s Q3 is near. Explore EPS growth, pipeline momentum, valuation, and dividend yield to see why it offers good ...
Repatha is the most extensively studied PCSK9 inhibitor, with clinical and real-world evidence across diverse populations and CV risk profiles. 7 The clinical benefits and safety of Repatha have been ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results